Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

CTF Presents Neurofibromatosis Pipeline at BIO CEO and Investors Conference

By February 13, 2011December 18th, 2023Awareness, Science & Research

For the second year in a row, the Children’s Tumor Foundation is among a small group of foundations invited to speak at the Biotechnology Industry Organization CEO and Investors Conference, today at the Waldorf-Astoria in New York City.   The BIO conference is a forum for emerging biotechs to meet investors and form partnerships with larger pharmas; for CTF, it is a valuable opportunity to present the pipeline of candidate neurofibromatosis drugs currently in preclinical testing and clinical trials, and to engage new industry partners who have drugs that could be future neurofibromatosis treatments.  CTF Chief Scientific Officer Dr. Kim Hunter-Schaedle will present at 3pm. This terrific opportunity builds on CTF’s recent invited presentation at the Milken Institute’s Partnering for Cures conference which can be viewed here.

Close Menu